All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
METER study: Real-world treatment patterns in patients with MF
Bookmark this article
|
Prior to the approval of ruxolitinib, HU was the most used 1L therapy for patients with MF.1 The impact of ruxolitinib and other JAKi approvals on the utilization of therapies remains unclear, and factors influencing changes in MF treatment choices in real-world settings are poorly understood.1 The multi-country, noninterventional, retrospective chart review METER study (NCT05444972) assessed treatment patterns, clinical outcomes, and healthcare resource utilization in patients with MF.1 Data were collected from 997 adult patients with primary or secondary MF from 66 sites across 14 countries between August 23, 2022, and November 14, 2023. Results were published in Blood Advances by Gupta, et al.1 |
| Key learnings |
| Ruxolitinib was the most common 1L (49.0%) and 2L (61.9%) treatment for MF, surpassing HU (1L, 40.2%; 2L, 28.4%). ∼50% of patients discontinued or switched treatments due to inadequate response (27.3%), disease progression (17.8%), or toxicity (11.5%). |
| The cumulative incidence of allo-HSCT was 2.2% at 24 weeks, increasing to 11.0% at 156 weeks in patients aged ≤70 years. |
|
Median OS for all patients was 79.1 months and was reduced with ruxolitinib (1L, 77.6 months; 2L+, 72.6 months) vs other therapies (142.3 months); possibly attributable to less aggressive disease. Risk factors such as age ≥65 years, male sex, high-risk classification, BMF ≥2, and TD were associated with reduced survival. |
| Among patients with ≥1 corresponding event, median hospital and ICU stay durations were 16 days and 5 days respectively, with a median of 12 transfusion events; highlighting persistent unmet needs in this patient population. |
Abbreviations: 1L, first-line; 2L, second-line; allo-HSCT, allogeneic hematopoietic stem cell transplantation; BMF, bone marrow fibrosis; HU, hydroxyurea; ICU, intensive care unit; JAKi, Janus kinase inhibitor; MF, myelofibrosis; OS, overall survival; TD, transfusion dependency.
- Gupta V, Tomuleasa C, Barranco G, et al. Real-world treatment patterns and healthcare resource use for patients with myelofibrosis: Results from the METER study. Blood Adv. 2024. Online ahead of print. DOI: 10.1182/bloodadvances.2024014625
More about...
Your opinion matters
14 votes - 60 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox